Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Identifying The Lethal Ancestral Clones of Metastatic Disease in Primary Prostate Cancer

EF 2017-18

Résumé
Most primary prostate cancer responds well to surgery and localized intervention, but 10% of men relapse with a more aggressive form of the disease known as castration-resistant prostate cancer (CRPC). Currently, there are no approved methods for predicting which patients with localized cancer will relapse after surgery. Moreover, though prostate cancer often presents with multiple and genetically-unique clones within the primary tumor, few studies have captured the entire picture of disease progression and shown from which clone the final, lethal tumor rose. This is partly because late-stage prostate cancers often spread to bone tissue, which is difficult and invasive to obtain tumor DNA from.New data from the Wyatt Lab suggests that genetic commonalities between early localized cancer and late-stage CRPC can be observed through DNA sequencing of matched archival prostate tissue and blood samples that were taken later in disease progression. I hypothesize that the ancestor clone of lethal disease is detectable in tissue from the original prostate tumor, and is distinguishable from clones without metastatic potential. My strong objective is to profile 50 genomes of matched primary and metastatic tumors, leveraging serial tissue biopsies and blood samples collected at the Vancouver Prostate Centre. Findings from this project will help define why some patients relapse after surgery, and could assist in determining patients at diagnosis who have particularly 'metastatic' tumor clones. Recent studies have established the survival benefit of earlier intervention in metastatic disease with certain therapeutics, and my findings may help identify patients suitable for even earlier therapy intensification prior to disease spread.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
386497
Name
Warner Evan
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying The Lethal Ancestral Clones of Metastatic Disease in Primary Prostate Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Clonal Evolution; Driver Mutations; Exome Sequencing; Liquid Biopsy; Mcrpc; Metastasis; Multifocal Primary Tumor; Prostate Cancer; Targeted Deep Sequencing
Abstract
Most primary prostate cancer responds well to surgery and localized intervention, but 10% of men relapse with a more aggressive form of the disease known as castration-resistant prostate cancer (CRPC). Currently, there are no approved methods for predicting which patients with localized cancer will relapse after surgery. Moreover, though prostate cancer often presents with multiple and genetically-unique clones within the primary tumor, few studies have captured the entire picture of disease progression and shown from which clone the final, lethal tumor rose. This is partly because late-stage prostate cancers often spread to bone tissue, which is difficult and invasive to obtain tumor DNA from.New data from the Wyatt Lab suggests that genetic commonalities between early localized cancer and late-stage CRPC can be observed through DNA sequencing of matched archival prostate tissue and blood samples that were taken later in disease progression. I hypothesize that the ancestor clone of lethal disease is detectable in tissue from the original prostate tumor, and is distinguishable from clones without metastatic potential. My strong objective is to profile 50 genomes of matched primary and metastatic tumors, leveraging serial tissue biopsies and blood samples collected at the Vancouver Prostate Centre. Findings from this project will help define why some patients relapse after surgery, and could assist in determining patients at diagnosis who have particularly 'metastatic' tumor clones. Recent studies have established the survival benefit of earlier intervention in metastatic disease with certain therapeutics, and my findings may help identify patients suitable for even earlier therapy intensification prior to disease spread.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Warner, Evan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~